What is Oakwood Labs?
Oakwood Labs is a distinguished global entity in sustained release drug delivery, offering comprehensive contract development and manufacturing services for long-acting injectable products. Leveraging over 28 years of expertise and its proprietary Chroniject technology, the company provides bespoke solutions across critical therapeutic areas such as oncology and central nervous system disorders. Their integrated approach encompasses feasibility studies, formulation refinement, and GMP aseptic manufacturing, ensuring scalable and high-quality production for pharmaceutical innovators transitioning projects from conception to market.
How much funding has Oakwood Labs raised?
Oakwood Labs has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
What's next for Oakwood Labs?
The recent major strategic investment signifies a pivotal moment for Oakwood Labs, likely enabling accelerated expansion of its manufacturing capabilities and further development of its Chroniject technology. This enterprise-level funding is expected to bolster its capacity to serve a growing pipeline of pharmaceutical partners, solidifying its role as a key player in bringing advanced drug delivery systems to market. The company's focus on specialized therapeutic areas suggests a strategic push to capture greater market share in high-demand segments.
See full Oakwood Labs company page
